Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
J Cosmet Dermatol. 2022 Nov;21(11):5519-5526. doi: 10.1111/jocd.15309. Epub 2022 Sep 4.
Cetirizine, a widely used agent for allergic disorders, has recently been topically used for treating androgenetic alopecia (AGA). We aimed to summarize the current evidence regarding the effectiveness and safety of topical cetirizine for treating AGA.
We searched Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized clinical trials.
We initially identified 102 records, of which, we included two RCTs and one non-randomized clinical trial, which were of moderate-to-high risk of bias. All included trials used 1% topical cetirizine as the intervention with various regimens. Topical cetirizine was likely to be more effective than a placebo for treating AGA. In comparison with topical minoxidil, topical cetirizine appears to be less effective for improving total and vellus hair density, but it might have a longer-lasting effect. Further, cetirizine might be as effective as minoxidil in improving hair diameter.
One percent topical cetirizine may serve as a choice for treating AGA, especially for patients with a negative response to topical minoxidil. In order to fully understand the role of topical cetirizine for AGA, additional well-designed RCTs are needed.
西替利嗪是一种广泛用于治疗过敏疾病的药物，最近已被局部用于治疗雄激素性脱发（AGA）。我们旨在总结目前关于局部西替利嗪治疗 AGA 的有效性和安全性的证据。
我们检索了 Ovid MEDLINE、Embase 和 Cochrane 对照试验中心注册库。我们纳入了随机对照试验（RCT）和非随机临床试验。
我们最初确定了 102 条记录，其中包括两项 RCT 和一项非随机临床试验，这些试验的偏倚风险为中高度。所有纳入的试验均使用 1%的局部西替利嗪作为干预措施，采用不同的方案。局部西替利嗪治疗 AGA 的疗效可能优于安慰剂。与局部米诺地尔相比，局部西替利嗪似乎对改善总发密度和毳毛密度的效果较差，但可能具有更长的疗效。此外，西替利嗪在改善头发直径方面可能与米诺地尔同样有效。
1%的局部西替利嗪可能可作为治疗 AGA 的选择，特别是对于对局部米诺地尔反应不佳的患者。为了全面了解局部西替利嗪在 AGA 中的作用，还需要更多设计良好的 RCT。
